Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA.
Am J Surg Pathol. 2011 Apr;35(4):615-9. doi: 10.1097/PAS.0b013e31820eb25b.
It is unknown whether ductal adenocarcinomas are more aggressive when matched for Gleason score (assigning the ductal component as Gleason pattern 4). Moreover, little is known whether a certain percentage of the ductal component is needed to account for its more aggressive behavior. Of 18,552 radical prostatectomies performed from 1995 to 2008, 93 cases with a ductal adenocarcinoma component were identified. Cases were classified based on their ductal/acinar ratio (<10%; ≥10% and <50%; ≥50%). There was no difference in the distribution of Gleason score 3+4=7 versus 4+3=7 between ductal and nonductal tumors, such that cases were combined as Gleason score 7. There was no age, race, and serum prostate-specific antigen difference between patients with and without ductal adenocarcinoma. Cases with ductal adenocarcinoma were less likely to be organ confined (36.6% vs 65.6%) and more likely to show seminal vesicle invasion (SVI) (19.3% vs 5.3%), P<0.0001. There was no difference in lymph node metastases or positive margins between cases with and without ductal features. An increasing percentage of the ductal component correlated with an increased risk of extraprostatic extension (P=0.04) and SVI (P<0.0001). To account for overall different Gleason scores between ductal and nonductal cases, and the effect of differing percentages of ductal features as well, the following analysis was carried out. For Gleason score 7 cases and ≥10% ductal differentiation, cases with ductal features were more likely to have nonfocal extraprostatic extension (64.0%) versus cases without ductal features (34.7%), P=0.002. In this group, there was no statistically significant difference in SVI or lymph node involvement between Gleason score 7 ductal and nonductal tumors. For Gleason score 7 cases with <10% ductal features, there was no difference in pathologic stage versus nonductal cases. There was no difference in pathologic stage between ductal and nonductal cases for Gleason score 8 to 10 cases, regardless of the percentage of the ductal component. This study shows that ductal adenocarcinoma admixed with Gleason pattern 3 is more aggressive than Gleason score 7 acinar cancer, as long as the ductal component is ≥10%. In cases with a very minor ductal component, these differences are lost. In addition, Gleason score 8 to 10 tumors with ductal features are not significantly more aggressive that acinar Gleason score 8 to 10 cancers in which the pure high-grade tumor, regardless of ductal features, determines the behavior.
在 Gleason 评分匹配的情况下(将导管成分评为 Gleason 模式 4),导管腺癌是否更具侵袭性尚不清楚。此外,对于导管成分需要达到一定比例才能表现出更具侵袭性的行为,我们知之甚少。在 1995 年至 2008 年间进行的 18552 例根治性前列腺切除术,发现 93 例有导管腺癌成分。病例根据其导管/腺泡比(<10%;≥10%和<50%;≥50%)进行分类。导管和非导管肿瘤之间,Gleason 评分 3+4=7 与 4+3=7 的分布没有差异,因此病例合并为 Gleason 评分 7。有导管腺癌的患者在年龄、种族和血清前列腺特异性抗原方面与无导管腺癌的患者没有差异。有导管腺癌的病例更不可能局限于器官(36.6%对 65.6%),更有可能出现精囊侵犯(SVI)(19.3%对 5.3%),P<0.0001。有导管特征的病例与无导管特征的病例在淋巴结转移或阳性切缘方面没有差异。导管成分的百分比增加与前列腺外延伸(P=0.04)和 SVI(P<0.0001)的风险增加相关。为了说明导管和非导管病例之间整体不同的 Gleason 评分,以及导管特征百分比的影响,进行了以下分析。对于 Gleason 评分 7 例和≥10%的导管分化,有导管特征的病例更有可能出现非局灶性前列腺外延伸(64.0%对无导管特征的病例 34.7%),P=0.002。在这组中,Gleason 评分 7 例导管和非导管肿瘤的 SVI 或淋巴结受累之间没有统计学差异。对于 Gleason 评分 7 例导管特征<10%的病例,与非导管病例相比,病理分期没有差异。Gleason 评分 8 至 10 例导管和非导管病例的病理分期没有差异,无论导管成分的百分比如何。本研究表明,只要导管成分≥10%,混合 Gleason 模式 3 的导管腺癌比 Gleason 评分 7 的腺泡癌更具侵袭性。在导管成分非常小的情况下,这些差异就会消失。此外,无论导管特征如何,Gleason 评分 8 至 10 例伴导管特征的肿瘤并不比单纯高级别肿瘤的 Gleason 评分 8 至 10 例腺泡癌更具侵袭性,而单纯高级别肿瘤决定了行为。